Aldesleukin: all 184 studies that test it
Page 2 of 2. Open to participants first (17), then studies with results posted, then the rest; newest registration first within each.
- IL-2 for Multi Drug Resistant Nephrotic SyndromeCompletedNCT02455908Phase 1/2
- Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid CancerWithdrawnNCT02390739Phase 1/2
- Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02316964Phase 1
- Adaptive Study of IL-2 Dose Frequency on Regulatory T Cells in Type 1 DiabetesCompletedNCT02265809Phase 1/2
- Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase II Study of Safety and Activity of Low Dose Interleukin-2CompletedNCT02059759Phase 2
- Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV MelanomaActive, not recruitingNCT01955460Phase 1
- Regulatory T Cells in Type 1 Diabetes Patients Treated With IL-2CompletedNCT01827735Phase 1/2
- Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell CarcinomaTerminatedNCT01758458Phase 1/2
- Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)Status unknownNCT01701479Phase 1/2
- Gene and Vaccine Therapy in Treating Patients With Advanced MalignanciesActive, not recruitingNCT01697527Phase 2
- HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic MelanomaTerminatedNCT01683188Phase 4
- Donor Cord Blood T-Cell Infusion After Stem Cell Transplant in Treating Patients With Relapsed Hematological MalignanciesTerminatedNCT01630564Phase 1
- Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric NeuroblastomaTerminatedNCT01404702Phase 1
- Dose-effect Relationship of Low-dose IL-2 in Type 1 DiabetesCompletedNCT01353833Phase 1/2
- Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With CancerTerminatedNCT01212887Phase 1
- Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic MelanomaTerminatedNCT01106235Phase 1
- Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2CompletedNCT01082926Phase 1
- Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV MelanomaTerminatedNCT00945269Phase 1/2
- Gene Therapy Using Anti-CEA Cells to Treat Metastatic CancerTerminatedNCT00923806Phase 1
- Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin LymphomaCompletedNCT00621452Phase 1
- Interferon-gamma or Aldesleukin and Vaccine Therapy in Treating Patients With Multiple MyelomaCompletedNCT00616720Phase 2
- Adoptive Immunotherapy, Aldesleukin, and Zoledronate in Treating Patients With Stage IV Kidney Cancer and Lung MetastasesCompletedNCT00588913Phase 1/2
- Evaluation of Clinical Efficacy and Immunologic Response After IL-2 Therapy in HCV-related Vasculitis PatientsCompletedNCT00574652Phase 1/2
- Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung CancerTerminatedNCT00569296Phase 1
- Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma PatientsActive, not recruitingNCT00553618Phase 2
- Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV MelanomaCompletedNCT00553306Phase 1/2
- Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV MelanomaCompletedNCT00438984Phase 1
- Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney CancerCompletedNCT00416429Phase 3
- Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney CancerCompletedNCT00304460Phase 1
- Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic MelanomaTerminatedNCT00303836Phase 2
- Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney CancerStatus unknownNCT00301990Phase 2
- Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal CancerCompletedNCT00278369Early Phase 1
- Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's LymphomaTerminatedNCT00250861Phase 2
- Treating Patients With Childhood Acute Myeloid Leukemia With Interleukin-2Status unknownNCT00149162Phase 3
- Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic MelanomaTerminatedNCT00138229Phase 2
- Safety and Effectiveness of Immunotherapy With Autologous HIV-Specific CD8 Cells in HIV Infected AdultsCompletedNCT00110578Phase 1
- Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic MelanomaCompletedNCT00091104Phase 1
- High-Dose Intravenous Interleukin-2 in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer) That Has Not Responded to Previous Low-Dose Intravenous or Subcutaneous Interleukin-2Status unknownNCT00080977Phase 2
- Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent NeuroblastomaTerminatedNCT00054405Phase 1
- Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell TransplantTerminatedNCT00052598Phase 1/2
- Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell TransplantationCompletedNCT00052520Phase 1/2
- Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis FungoidesTerminatedNCT00052377Phase 1/2
- Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan TreatmentsCompletedNCT00045877Phase 2/3
- Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.CompletedNCT00045864Phase 2
- Interleukin-2 (IL-2) Treatment for HIV Infected Patients Who Have Interrupted Their Anti-HIV Drug TherapyCompletedNCT00038259Not applicable
- Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney CancerCompletedNCT00032188Phase 2
- Biological Therapy in Treating Women With Stage IV Breast CancerCompletedNCT00027807Phase 1
- Interleukin-2 in Treating Patients With Metastatic Kidney CancerCompletedNCT00018941Phase 3
- Effect of Interleukin-2 on HIV Treatment InterruptionCompletedNCT00015704Not applicable
- Rituximab Plus Interleukin-2 in Treating Patients With Hematologic CancerCompletedNCT00010192Phase 1
- Interleukin-2 in Treating Children Who Have Undergone Bone Marrow Transplantation for Acute Myeloid LeukemiaCompletedNCT00009698Phase 1
- Interleukin-2 in Treating Patients With Metastatic Kidney CancerCompletedNCT00006864Phase 4
- Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00006363Phase 3
- A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV InfectionCompletedNCT00006154Phase 3
- Vaccine Plus Interleukin-2 in Treating Patients With Advanced MelanomaCompletedNCT00005949Phase 2
- Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary SyndromeTerminatedNCT00005788Phase 2
- Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid TumorsCompletedNCT00005604Phase 1
- Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With NeuroblastomaCompletedNCT00005576Phase 1
- Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic CancerCompletedNCT00003962Phase 1
- Interleukin-2 in Treating Children With Stage IV Neuroblastoma Who Have Received Induction Therapy and Peripheral Stem Cell TransplantationStatus unknownNCT00003743Phase 2
- Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer That Has Been Removed With SurgeryStatus unknownNCT00003604Phase 2
- Interleukin-2 in Treating Patients With Relapsed or Refractory Acute Myelogenous LeukemiaCompletedNCT00003148Phase 2
- Biological Therapy in Previously Treated Patients With Non-small Cell Lung CancerStatus unknownNCT00003090Phase 2
- Inhaled Interleukin-2 in Treating Patients With Metastatic or Unresectable CancerTerminatedNCT00003009Phase 1
- Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With MelanomaCompletedNCT00002882Phase 3
- Interleukin-2 in Treating Patients With Metastatic or Recurrent Kidney CancerStatus unknownNCT00002846Phase 2
- Interleukin-2 in Treating Patients With Metastatic MelanomaStatus unknownNCT00002845Phase 2
- Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic SyndromeCompletedNCT00002798Phase 3
- Interleukin-2 in Treating Patients With Myelodysplastic SyndromeCompletedNCT00002746Phase 1
- Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or OropharynxStatus unknownNCT00002702Phase 3
- Interleukin-2 in Treating Patients With Mycosis FungoidesCompletedNCT00002687Phase 1
- Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's LymphomaCompletedNCT00002649Phase 3
- Safety and Effectiveness of L2-7001 (Interleukin-2) in HIV-Positive Patients Receiving Anti-HIV TherapyStatus unknownNCT00002449Phase 1
- A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) RetinitisCompletedNCT00002321Phase 1
- A Phase I Study of Subcutaneously Administered Proleukin (Aldesleukin) in HIV-Infected PatientsCompletedNCT00002107Phase 1
- Effectiveness of Interleukin-2 (IL-2) Plus Anti-HIV Therapy in HIV-Positive PatientsCompletedNCT00001131Not applicable
- A Study to Evaluate the Effects of Giving Proleukin (rIL-2) to HIV-Positive Patients With CD4 Counts Greater Than 300 Cells/mm3CompletedNCT00000949Phase 3
- Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3CompletedNCT00000948Phase 2
- A Study to Evaluate the Effects of Giving IL-2 Alone to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3 Who Do Not Wish to Receive Anti-HIV TherapyCompletedNCT00000909Phase 2
- A Study to Evaluate the Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3CompletedNCT00000889Phase 2
- A Study to Test the Safety of Recombinant Interleukin-2 (rIL-2) in HIV-Infected ChildrenCompletedNCT00000849Phase 1
- The Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3CompletedNCT00000825Phase 2
- Subcutaneously Administered Aldesleukin ( Interleukin-2; IL-2 ) Therapy in HIV-Infected PatientsCompletedNCT00000821Phase 1
- A Phase II Study of Low-Dose Interleukin-2 by Subcutaneous Injection in Combination With Antiretroviral Therapy Versus Antiretroviral Therapy Alone in Patients With HIV-1 Infection and at Least 3 Months Stable Antiretroviral TherapyCompletedNCT00000820Phase 2